US FDA warns Novo for second time about misleading drug advertising | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. REUTERS/Lee Smith [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]Follow[U.S. Food and Drug Administration]FollowMarch 3 (Reuters) - The U.S. Food and Drug Administration has told Novo Nordisk [(NO ...

整理 | GLP1减重宝典内容团队 2026年3月3日，诺和诺德宣布其司美格鲁肽注射液的新适应症在中国已提交上市申请，并拟纳入优先审评。这一新适应症旨在治疗伴有中至重 度肝纤维化的代谢相关脂肪性肝炎（MASH）患者，特别是针对F2-F3期的非肝硬化成人患者。 司美格鲁肽的全球影响力 司美格鲁肽作为诺和诺德的旗舰药物，早在2025年8月已获得美国FDA批准，用于治疗伴有中度到重度肝纤维化的非肝硬化MASH患者，且要 求联合低热量饮食和增加体力活动。此次中国的申报，是基于ESSENCE临床试验的部分结果。该试验评估了每周一次注射2.4mg司美格鲁肽的 疗效，结果显示，司美格鲁肽在改善肝纤维化和脂肪性肝炎消退方面，均表现出优于安慰剂的统计学显著性。 临床试验结果 ESSENCE试验的第一阶段结果表明，使用司美格鲁肽的患者在改善肝纤维化和消退脂肪性肝炎方面，达到了以下临床指标： 在第72周时，36.8%的患者实现了"肝纤维化改善且无脂肪性肝炎恶化"，而安慰剂组仅为22.4%。 62.9%的患者达到了"脂肪性肝炎消退且无肝纤维化恶化"的效果，而安慰剂组为34.3%。 作为诺和诺德的明星药物，司美格鲁肽的销售表现十分亮眼 ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated high demand for oral weight loss drugs. Novo's site in Monksland, Athlone, is one of 16 facilities the company has across the world. The expansion of the 45-acre tabletting facility is expected to be completed by 2028, though construction has already begun. The site's existing 260 employees will focus on delivering oral glucagon-like peptide-1 receptor agonists (GLP- 1RAs). The Danish ...

Company Strategy - Roche aims for a double-digit market share in the weight loss market, seeking to close the gap with its competitor Novo Nordisk [1] - The CEO of Roche, Thomas Schinecker, expressed the expectation to be among the top three players in the market at the very least [1]

// 热点头条 // 1. 英伟达：宣布向光模块龙头Coherent与Lumentum分别注资20亿美元，合作开发先进光学技术；同时 计划发布专为OpenAI等客户定制的全新AI处理器，整合Groq设计的芯片，预计下月在GTC开发者大会 公布。此外，公司还联手诺基亚与思科等巨头推进AI-RAN与6G生态，签署多项商用合作，发布电信场 景LTM与自主网络蓝图。 2. 苹果：推出了其入门级智能手机的最新版本iPhone 17e，以及一款速度更快的iPad Air，起售价依然为 599美元，拉开了新一轮产品发布的序幕；已暂时关闭其位于阿联酋的全部5家Apple Store零售店，涵盖 阿布扎比3家门店和迪拜2家门店，关闭状态将至少持续至当地时间3月4日，公司未说明具体关闭原因， 但强调将密切关注当地情况并及时更新门店运营信息。 3. 阿里巴巴：阿里巴巴集团内部已完成对AI核心品牌的统一。调整后，阿里巴巴AI的总称和核心品牌 确定为"千问"。其中，千问大模型（Qwen）涵盖基础大模型和专业领域模型，千问APP是阿里巴巴在C 端的旗舰AI应用。3月2日，千问首款AI硬件——"千问AI眼镜"发布，开启线上线下全渠道"0元 ...

In this articleNVOLLYNVONovo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, in what has been described as one of the strongest launches ever. "With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities f ...

Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee representatives were elected for the next four years: Semsi Kilic Madsen (new)Mette Bøjer Jensen (re-elected)Elisabeth Dahl Christensen (re-elected)Désirée Jantzen Asgreen (new) The following were elected as substitutes for the employee-elected board members: Trine Hartvig KristiansenTamara SchmidtTanja VillumsenHass ...

整理 | GLP1减重宝典内容团队 3月2日，诺和诺德宣布将投资4.32亿欧元（约5.06亿美元），扩建并改造其位于爱尔兰阿斯隆 Athlone（Monksland）的口服制剂工厂，为当前 和未来的口服GLP-1治疗药物新增制造能力。该项目已启动建设，工厂现有约260名员工将继续在升级后的设施内生产口服药物；扩建覆盖约45 英亩（约18公顷）用地，施工高峰期预计带来最多500个建筑岗位，并计划在2027年底至2028年分阶段完工。 诺和诺德对外给出的定位也很明确：阿斯隆将成为其面向美国以外全球市场的关键口服产能枢纽。换句话说，这不是一次普通的厂房扩容，而 是把口服GLP-1的供给链条提前做厚，给未来更大规模的放量留出余地。 产能扩张背后，是诺和诺德最近一段时间在口服与新机制管线上的连续动作。2月25日，公司与美国初创企业Vivtex达成合作，交易总价值最高 可达21亿美元，目标是提升生物大分子实现口服给药的可行性，诺和诺德将负责后续开发、生产与商业化，Vivtex则获得首付款、里程碑款与 版税等。对诺和诺德来说，这类合作的意义在于把口服化的技术赌注往前推：如果未来更多代谢类大分子能被做成口服剂型，产能与工艺平 ...

Key Takeaways Novo Nordisk stock fell 21% after CagriSema lost to Zepbound in the phase III REDEFINE 4 obesity study.Lilly's orforglipron beat Rybelsus in ACHIEVE-3, cutting A1C by 2.2% and weight by 9.2% at 52 weeks.Novo Nordisk plans to cut U.S. list prices of Wegovy, Ozempic and Rybelsus to $675 monthly by 2027.Novo Nordisk (NVO) has endured a brutal week, with its shares plunging 21% after a series of disappointing clinical results and mounting pricing pressures erased virtually all the gains accumulate ...